|

Topotecan Clinical Trials

30 actively recruiting trials across 12 locations

▼ -1 trial since May 2026

Also known as: Hycamptamine, Hycamtin, Hycamtin®, TPT, Topotecan Lactone +1 more

Pipeline

Early 1: 1Phase 1: 5Phase 2: 5Phase 3: 15Phase 4: 1Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • Luye Pharma Group Ltd.2
  • Hansoh BioMedical R&D Company2
  • Daiichi Sankyo2
  • Children's Oncology Group2
  • Washington University School of Medicine1

Indications

Other13 trials

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
Phase 1/2
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Phase 3
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Phase 3
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3
High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
Early 1
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Phase 3
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Phase 3
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
Phase 3
Topotecan and Melphalan for Retinoblastoma
Phase 3
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Phase 4

Birmingham, Alabama5 trials

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Children's Hospital of Alabama

Phase 2
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

University of Alabama at Birmingham

Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Children's Hospital of Alabama

Phase 3
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

University of Alabama at Birmingham (Children's of Alabama)

Phase 1
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Hospital of Alabama

Phase 3

New York, New York2 trials

Chronic CED of TPT for Recurrent Malignant Glioma

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital

Phase 1
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 2

Anchorage, Alaska1 trial

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Alaska Women's Cancer Care

Phase 2/3

Phoenix, Arizona1 trial

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Phoenix Children's Hospital

Phase 1

Hot Springs, Arkansas1 trial

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Genesis Cancer and Blood Institute

Phase 3

Springdale, Arkansas1 trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Highlands Oncology Group

Phase 3

Palo Alto, California1 trial

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Lucille Packard Children's Hospital Stanford

Phase 2

Fort Lauderdale, Florida1 trial

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Research Site

Phase 3

Peoria, Illinois1 trial

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

OSF Saint Francis Medical Center

Phase 1

St Louis, Missouri1 trial

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Washington University School of Medicine/St. Louis Children's Hospital

Phase 1

Hershey, Pennsylvania1 trial

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Penn State Milton S. Hershey Medical Center and Children's Hospital

Phase 2

Philadelphia, Pennsylvania1 trial

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.